Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $102.67 +0.52 (+0.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$101.16▼$104.5850-Day Range$101.15▼$114.4452-Week Range$36.90▼$117.23Volume1.05 million shsAverage Volume1.27 million shsMarket Capitalization$12.61 billionP/E RatioN/ADividend YieldN/APrice Target$101.19 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Natera alerts: Email Address Natera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1.4% Downside$101.19 Price TargetShort InterestBearish5.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 22 Articles This WeekInsider TradingSelling Shares$12.60 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.43) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector758th out of 936 stocksMedical Laboratories Industry17th out of 18 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.02% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Natera has recently decreased by 3.29%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 2.5 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Natera this week, compared to 7 articles on an average week.Search Interest15 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,600,885.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.43) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -32.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -32.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 16.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesJuly 25 at 5:46 AM | insidertrades.comMichael Burkes Brophy Sells 499 Shares of Natera, Inc. (NASDAQ:NTRA) StockJuly 24 at 5:34 AM | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 549 Shares of StockJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 19, 2024 | insidertrades.comSteven Leonard Chapman Sells 5,496 Shares of Natera, Inc. (NASDAQ:NTRA) StockJuly 3, 2024 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,700 Shares of StockJuly 3, 2024 | insidertrades.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 4,983 Shares of StockJuly 26 at 12:03 PM | finance.yahoo.comNew MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell CarcinomaJuly 25 at 10:27 AM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Natera (NTRA) and Edwards Lifesciences (EW)July 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 25 at 6:50 AM | americanbankingnews.comSolomon Moshkevich Sells 549 Shares of Natera, Inc. (NASDAQ:NTRA) StockJuly 24 at 8:13 AM | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 2,638 SharesJuly 22, 2024 | americanbankingnews.comLeerink Partnrs Analysts Lower Earnings Estimates for Natera, Inc. (NASDAQ:NTRA)July 20, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Shares Down 7% on Insider SellingJuly 19, 2024 | benzinga.comHere's How Much You Would Have Made Owning Natera Stock In The Last 5 YearsJune 17, 2024 | businesswire.comNatera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant PatientsJune 3, 2024 | seekingalpha.comNatera: Overdue For A BreatherJune 3, 2024 | businesswire.comNatera to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 30, 2024 | businesswire.comNatera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024See More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$101.19 High Stock Price Target$142.00 Low Stock Price Target$68.00 Potential Upside/Downside-1.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-30.24% Pretax Margin-30.19% Return on Equity-49.72% Return on Assets-26.08% Debt Debt-to-Equity Ratio0.36 Current Ratio4.12 Quick Ratio3.98 Sales & Book Value Annual Sales$1.08 billion Price / Sales11.65 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book16.12Miscellaneous Outstanding Shares122,800,000Free Float113,470,000Market Cap$12.61 billion OptionableOptionable Beta1.48 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsFresenius Medical CareNYSE:FMSQuest DiagnosticsNYSE:DGXOption Care HealthNASDAQ:OPCHPACS GroupNYSE:PACSHims & Hers HealthNYSE:HIMSView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 119,906 shares on 7/26/2024Ownership: 0.801%ARK Investment Management LLCBought 92,958 shares on 7/26/2024Ownership: 0.338%EFG Asset Management North America Corp.Sold 27,872 shares on 7/26/2024Ownership: 0.055%K.J. Harrison & Partners IncSold 12,800 shares on 7/26/2024Ownership: 0.007%RiverPark Advisors LLCBought 283 shares on 7/26/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA stock has increased by 63.9% and is now trading at $102.67. View the best growth stocks for 2024 here. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings results on Thursday, May, 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.16. The business's revenue for the quarter was up 52.1% on a year-over-year basis. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Top institutional shareholders of Natera include Allspring Global Investments Holdings LLC (0.80%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Chevy Chase Trust Holdings LLC (0.35%) and ARK Investment Management LLC (0.34%). Insiders that own company stock include Matthew Rabinowitz, Jonathan Sheena, Steven Leonard Chapman, Daniel Rabinowitz, Solomon Moshkevich, John Fesko, Michael Burkes Brophy, Herm Rosenman, James Healy, Gail Boxer Marcus, Todd C Cozzens, Rowan E Chapman, Robert Alan Schueren and Roelof Botha. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV) and Aegean Marine Petroleum Network (ANW). This page (NASDAQ:NTRA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTRA Stock Alerts